Ga-68-FAPI-46

PreclinicalSmall molecule

KKoo Foundation Sun Yat-Sen Cancer Center

Ga-68-FAPI-46 is one of 14 small molecule programs targeting Recurrence. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RecurrenceRecruiting

RecurrencePreclinical

Recruiting

Competition

Competitive Landscape

14 competitors in Recurrence

#DrugCompanyPhaseTrials

Aromasin

Pfizer

Phase 2

2 2

Trodelvy

Gilead

Phase 2

1 3

Tecentriq

Roche

Phase 2

1 4

Erleada

Johnson & Johnson

Phase 2

1 5

Kisqali

Novartis

Phase 2

1 6

Femara

Novartis

Phase 2

1 7

Nolvadex

AstraZeneca

Phase 2

1 8

Arimidex

IIstituto Clinico Humanitas

Phase 2

1 9

Faslodex

FFresenius Kabi USA, LLC

Phase 2

1 10

Androgen Deprivation Therapy

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Recurrence1 trial

Ga-68-FAPI-46 PET for CRC Recurrence Detection in Elevated CEA

Recruiting·KKoo Foundation Sun Yat-Sen Cancer Center·N/A·NCT06769828·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ga-68-FAPI-46. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ga-68-FAPI-46 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ga-68-FAPI-46. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Koo Foundation Sun Yat-Sen Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKoo Foundation Sun Yat-Sen Cancer Center

Ga-68-FAPI-46

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Recurrence1 trial

References

Drug Info

Quick Facts

Related News